Free Beta: Procurement discovery is free; verify every opportunity on SAM.gov. Source status
OtherClosing soon

6550--INTENT TO SOLE SOURCE - Buffalo VA Thermo Fisher GENEXUS Reagents

VETERANS AFFAIRS, DEPARTMENT OF › 242-NETWORK CONTRACT OFFICE 02 (36C242)

Response deadlineAug 27, 2026 10:00 AM EDT
View official notice on SAM.gov (opens in a new tab)
Verify before acting. Users must verify deadlines, amendments, attachments, eligibility, and submission requirements on the official SAM.gov notice. Read the Data Disclaimer.

Key decision factors

Response deadline
Aug 27, 2026 10:00 AM EDT
Posted
Aug 20, 2026 12:00 AM EDT
Notice type
Special Notice
Set-aside
Not provided or not applicable
NAICS
325413
PSC
6550
Place of performance
Not specified
Current status
Closing soon

Notice details

Official status
Closing soon
Normalized group
Other
Notice ID
e2ab630611094426911b176eef82f87b
Solicitation number
36C24226Q0938

Description

Displayed as sanitized plain text from SAM.gov. Retrieved Aug 21, 2026 8:09 PM EDT.

This is a notice of intent to award a sole source contract and is not a request for quotes. The Department of Veterans Affairs on behalf of the Buffalo VA Medical Center intends to award a Firm Fixed Price (FFP), sole source action to Large Businesses (LB). Name of Contractor: Thermo Fisher Scientific Street Address: 5781 Van Allen Way City, State, Zip: Carlsbad, CA 92008 USA The Pathology and Laboratory Medicine Department requires reagents and supplies outlined in this procurement to continue to perform patient testing on the Thermo Fisher Genexus instrument, and Genexus Purification System. Both instruments are owned and operated by the Buffalo VAMC Pathology and Laboratory Medicine department. The Genexus instrument utilizes the Oncomine Precision Assay which enables simultaneous detection of biomarkers across 50 genes, including key targets within EGFR, BRAF, KRAS, ALK, ROS1, NTRK, RET, HER2, and others, from solid tissue samples. Genomic profiling of tumors from cancer patients facilitates molecular-guided therapy. The OPA NGS panel has significant clinical utility in cancer treatment by providing comprehensive genomic profiling of a tumor sample, allowing healthcare providers to identify actionable genetic alterations and select the most appropriate targeted therapies for a patient based on their specific tumor mutations, leading to more effective treatment plans. Item number Description Quantity A40261 Ion Torrent Genexus Barcodes 1-32- AS HD 12 A40266 Ion Torrent Genexus Pipette tips 7 4483354 96-well plates (20/box) 4 A40269 Ion Torrent GX5 Chip and Genexus Coupler 6 A40271 Genexus Sequencing Kit 6 AB0626 Adhesive Foil Seals Microp Lates oe PCR Plates 1 A40263 Genexus Templating Strips 3 and 4-GX5 (8/BOX) 7 A45539 Genexus FFPE DNA/RNA Purification Kit 6 A46291 Oncomine Precision Assay GX 12 This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The statutory authority for this sole source procurement is prescribed by FAR 13.105(a). The Department of Veterans Affairs, Buffalo, NY location intends to issue a sole source award contract to Thermo Fisher Scientific, all responsible sources may submit a capability statement demonstrating the ability to provide the requested services, which shall be considered by the agency before the intended award date. The Government shall not reimburse interested sources for any information provided. No requests for capability briefings will be honored. NAICS Code: 325413 In-Vitro Diagnostic Substance Manufacturing Veterans Health Administration prohibits the use of gray market items in their Medical Centers. Gray market items are considered to be items outside of the original equipment manufacturer s intended distribution channels. This notice is not a request for quotes; however, all responsible sources may submit a capability statement which shall be considered by the Government. All capability statements must be received by no later than 10:00 AM Eastern Standard Time on August 27, 2025. Responses to be submitted to Morgan Weeks, Contracting Officer at Morgan.Weeks1@va.gov. A determination by the Government not to compete this proposed contract based on responses to this notice is solely within the discretion of the Gove

Attachments

1 attachment reported by SAM.gov

Files are hosted by SAM.gov. Open the official notice to review and download them.

View attachments on SAM.gov (opens in a new tab)

Contacts

Morgan.Weeks1@va.gov
Primary — Morgan Weeks
Morgan.Weeks1@va.gov
Phone: (607) 664-4708

Personalized relevance

Would this fit your company?

Create company profile information with a free account to see a deterministic, explainable relevance score. Matching does not determine eligibility or win probability.

Create Free Account

Pursuit risk (separate from your match score)

Strong pursuit warning

This notice contains language indicating a sole-source or otherwise restricted procurement. Review the cited evidence before investing time in a response.

Detected in

  • Notice title“6550--INTENT TO SOLE SOURCE - Buffalo VA Thermo Fisher GENEXUS Reagents”

Pursuit risk is evaluated separately from your match score above and never changes it. This is not a legal or eligibility determination — verify against the official SAM.gov notice and attachments.